![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ATHERSYS EXTENDS PARTNERSHIP WITH BRISTOL-MYERS SQUIBB TO PROVIDE DRUG TARGETS
ATHERSYS EXTENDS PARTNERSHIP WITH BRISTOL-MYERS SQUIBB TO PROVIDE DRUG TARGETS
January 6, 2006
Athersys Inc. announced today that it has extended its existing alliance with
Bristol-Myers Squibb Company (NYSE: BMY - News) to apply its patented RAGE technology
to provide Bristol-Myers Squibb with additional validated drug targets for high-throughput
screening and lead optimization in multiple therapeutic areas. The new agreement
will extend the alliance for up to three years with a guaranteed minimum number
of targets to be supplied by Athersys annually.
Yahoo
News
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct